Search research articles
Contact Us
Filters
Showing results (221-230 of 237) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andrés Redondo, et al.
Virchows Archiv : an International Journal of Pathology
|
February 19, 2021
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Carien L Creutzberg, Ignace Vergote, et al.
Journal of the National Cancer Institute
|
June 20, 2013
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation
Alain G Zeimet, Daniel Reimer, Monica Huszar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
The Lancet. Oncology
|
August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The New England Journal of Medicine
|
October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
The Lancet. Oncology
|
November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni, Weixiu Luo, Per Karlsson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes
Christian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Bradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 237) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial
Philipp Harter, Frederik Marmé, Andrés Redondo, et al.
Virchows Archiv : an International Journal of Pathology
|
February 19, 2021
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Carien L Creutzberg, Ignace Vergote, et al.
Journal of the National Cancer Institute
|
June 20, 2013
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation
Alain G Zeimet, Daniel Reimer, Monica Huszar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2023
Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Ignace Vergote, Susana Banerjee, et al.
The Lancet. Oncology
|
August 5, 2024
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
Nicoletta Colombo, Elena Biagioli, Kenichi Harano, et al.
The New England Journal of Medicine
|
October 9, 2016
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, et al.
The Lancet. Oncology
|
November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Marco Colleoni, Weixiu Luo, Per Karlsson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 21, 2026
Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes
Christian Marth, Domenica Lorusso, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
Bradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
Page
of 24